CHANGING THE PARADIGM
OF MEDICINE
Microviable Therapeutics is developing a novel category of microbiota-based biotherapeutic products for infectious diseases, skin and neurological disorders. Our current strategy includes two different products: a unique in its kind complete microbiota and live biotherapeutic products (LBPs) based on rationally design bacterial consortia. We have several preclinical stage programs aiming to perform clinical trials by the end of 2022.
Our preclinical stage programs and related information are disclosed below:
| Program | Indication | Product Type(s) | Discovery | Preclinical | Clinical |
|---|---|---|---|---|---|
| MVT-201 | Infectious Diseases | Complete Microbiota HPM® | |||
| MVT-601 | Skin disorder | Bacterial consortia & HPM® | |||
| MVT-801 | Neurological disorder | Complete Microbiota HPM® | |||
| MVT-2401 | Oncology | Bacterial consortia & HPM® | |||
| MVT-701 | Healthy ageing | Bacterial consortia | |||
| MVT-1001 | Sports performance | Bacterial consortia | |||
| MVT-2501 | Mental health | Bacterial consortia |
Program: MVT-Prj-601
Indication: Atopic Dermatitis
Discovery Fase
Program: MVT-Prj-701
Indication: Longevity
Discovery Fase
Program: MVT-Prj-1001
Indication:Sports Performance
Data collection fase
Program: MVT-201
Indication: Infectious Diseases
Product type: Complete Microbiota HiPMTM
Preclinical fase
Program: MVT-601
Indication: Skin disorder
Product type: Bacterial consortia
Discovery fase
Program: MVT-801
Indication: Neurological disorder
Product type: Bacterial consortia
Preclinical fase
Over the last four years we have built up our platform powered by innovation leading to tangible products and technologies. Microviable Therapeutics currently have one of the largest and most diverse proprietary, gut bacterial strain culture collections as well the technology to isolate and preserve viable microbiota for long-term without altering its original identity.